Why is ehlers danlos so common now

Overview

Ehlers-Danlos syndromes (EDS) are a group of inherited connective tissue disorders characterized by joint hypermobility, skin hyperextensibility, and tissue fragility. First described by physicians Edvard Ehlers in 1901 and Henri-Alexandre Danlos in 1908, these conditions were historically rare diagnoses. The perception of increased prevalence stems largely from diagnostic evolution rather than actual disease emergence. Before the 1990s, EDS was primarily diagnosed clinically with limited genetic confirmation. The 1997 Villefranche classification system organized EDS into six major types, but this was superseded by the 2017 International Classification that defined 13 subtypes with specific genetic criteria. This reclassification, combined with growing medical education about EDS, has dramatically changed diagnostic patterns. Patient advocacy organizations like The Ehlers-Danlos Society, founded in 1985, have played crucial roles in raising awareness and supporting research. The increased visibility of EDS in medical literature and public discourse has created the impression of rising incidence, though the genetic basis suggests stable inheritance patterns.

How It Works

EDS results from genetic mutations affecting collagen production, processing, or structure—the primary protein providing strength and elasticity to connective tissues throughout the body. These mutations follow autosomal dominant or recessive inheritance patterns, meaning they're passed through families. The diagnostic process involves clinical evaluation using tools like the Beighton score for joint hypermobility, assessment of skin features, and family history. Since the 1990s, genetic testing has become increasingly important, particularly for classical, vascular, and other rare EDS types with identified gene mutations. For hypermobile EDS (hEDS), which lacks a confirmed genetic marker, diagnosis relies on clinical criteria established in 2017. Increased diagnosis rates stem from multiple factors: improved physician education about EDS symptoms beyond the classic triad, better recognition of comorbid conditions like dysautonomia and mast cell activation syndrome, and patient self-advocacy facilitated by online resources. The expansion of genetic testing availability and insurance coverage since 2000 has also contributed to more confirmed diagnoses.

Why It Matters

The apparent increase in EDS diagnoses has significant implications for healthcare systems and patients. More accurate identification enables proper management of potentially life-threatening complications, particularly in vascular EDS where arterial rupture risks require monitoring. For the majority with non-vascular types, diagnosis provides validation of often-dismissed symptoms and access to appropriate physical therapy, pain management, and lifestyle adaptations. The growing recognition of EDS has spurred research investment, with the NIH increasing funding for connective tissue disorder studies by approximately 40% between 2010-2020. This benefits not only EDS patients but also advances understanding of related conditions like osteoarthritis and cardiovascular diseases. However, increased awareness has also created challenges, including potential overdiagnosis and strain on specialized clinics with long wait times. The evolving understanding of EDS prevalence directly impacts resource allocation, medical education, and support services for this historically underrecognized patient population.